News Releases

Date	Title and Summary	View
Jul 16, 2018	Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
Jul 11, 2018	Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
Jun 19, 2018	Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results NEW BRUNSWICK, N.J. , June 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17 , to review second-quarter results. Alex Gorsky , Chairman and Chief Executive Officer and Joseph J.
Jun 18, 2018	FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio Next generation LASIK platform that measures the eye inside and out to enable highly precise personalized vision correction Only available LASIK platform indicated for monovision LASIK in presbyopic myopic patients 25 times more precise than the traditional way of measuring refractive errors which rely on subjective input(1)
Jun 12, 2018	Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc. NEW BRUNSWICK, N.J. , June 12, 2018 /CNW/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018 , to acquire its LifeScan business for approximately $2.1 billion . LifeScan, Inc.
Jun 06, 2018	Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP) NEW BRUNSWICK, N.J. , June 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Fortive Corporation (NYSE: FTV) to acquire its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.
Jun 03, 2018	Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer
May 30, 2018	Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma Planned Start of Clinical Program and Clearance of U.S. Food and Drug Administration Investigational New Drug Application Reflect Progress in Strategic Partnership with Legend Biotech
May 29, 2018	Johnson & Johnson to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference NEW BRUNSWICK, N.J. , May 29, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12 , at the Terranea Resort in Rancho Palos Verdes , California. Tom Cavanaugh, President, Oncology, Janssen
May 22, 2018	Johnson & Johnson to Participate in the Jefferies 2018 Global Healthcare Conference